Profiling response to carmustine/bevacizumab in recurrent glioblastoma.

被引：0
|
作者：
Rojas, Leonardo
Cardona, Andres F.
Wills, Beatriz
Arrieta, Oscar
Vargas, Carlos A.
Carranza, Hernan
Otero, Jorge M.
Useche, Nicolas
Bermudez, Sonia
Jimenez, Enrique
Hakim, Fernando
Balana, Carmen
机构：
[1] Hosp Univ San Ignacio, Dept Oncol, Ctr Javeriano Oncol, Bogota, Colombia
[2] Clin Country, Clin & Traslat Oncol Grp, Bogota, Colombia
[3] Fdn Clin & Appl Canc Res, Bogota, Colombia
[4] Inst Nacl Cancerol INCAN, Mexico City, DF, Mexico
[5] Fdn Santa Fe Bogota, Neuroradiol Sect, Bogota, Colombia
[6] Fdn Santa Fe Bogota, Neurosurg Dept, Bogota, Colombia
[7] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2059
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma
    Cardona, A. F.
    Rojas, L.
    Wills, B.
    Ruiz-Patino, A.
    Abril, L.
    Hakim, F.
    Jimenez, E.
    Useche, N.
    Bermudez, S.
    Mejia, J. A.
    Ramon, J. F.
    Carranza, H.
    Vargas, C.
    Otero, J.
    Archila, P.
    Rodriguez, J.
    Rodriguez, J.
    Behaine, J.
    Gonzalez, D.
    Jacobo, J.
    Cifuentes, H.
    Feo, O.
    Penagos, P.
    Pineda, D.
    Ricaurte, L.
    Pino, L. E.
    Vargas, C.
    Marquez, J. C.
    Mantilla, M. I.
    Ortiz, L. D.
    Balana, C.
    Rosell, R.
    Zatarain-Barron, Z. L.
    Arrieta, O.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (10): : 1364 - 1373
  • [2] A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma
    A. F. Cardona
    L. Rojas
    B. Wills
    A. Ruiz-Patiño
    L. Abril
    F. Hakim
    E. Jiménez
    N. Useche
    S. Bermúdez
    J. A. Mejía
    J. F. Ramón
    H. Carranza
    C. Vargas
    J. Otero
    P. Archila
    J. Rodríguez
    J. Rodríguez
    J. Behaine
    D. González
    J. Jacobo
    H. Cifuentes
    O. Feo
    P. Penagos
    D. Pineda
    L. Ricaurte
    L. E. Pino
    C. Vargas
    J. C. Marquez
    M. I. Mantilla
    L. D. Ortiz
    C. Balaña
    R. Rosell
    Z. L. Zatarain-Barrón
    O. Arrieta
    Clinical and Translational Oncology, 2019, 21 : 1364 - 1373
  • [3] Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
    Ghiaseddin, Ashley
    Reardon, David A.
    Massey, Woody
    Mannerino, Alexandra
    Lipp, Eric S.
    Herndon, James E.
    McSherry, Frances
    Desjardins, Annick
    Randazzo, Dina M.
    Vlahovic, Gordana
    Friedman, Henry S.
    Peters, Katherine B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.
    Melhem, Jawad
    Tahir, Ali
    Calabrese, Eirena
    Granovskaya, Inga
    Atenafu, Eshetu G.
    Sahgal, Arjun
    Lim-Fat, Mary Jane
    Perry, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Efficacy and safety study of fotemustine and bevacizumab in patients with recurrent glioblastoma.
    Escudero, Laura Sanchez
    Urbano, Maria Amor
    Garces, Maria Yeray Rodriguez
    Murillo, Fatima Toscano
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Pathway profiling of glioblastoma.
    Mischel, P
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6269S - 6269S
  • [7] Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.
    Bota, D. A.
    Eroglu, Z.
    Reardon, D. A.
    Fu, B. D.
    Norfleet, J.
    Desjardins, A.
    Linskey, M. E.
    Peters, K.
    Friedman, H. S.
    Vredenburgh, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Response to regorafenib of recurrent glioblastoma. A clinical and NGS study
    Martini, M.
    D'Alessandris, Q. G.
    Cenci, T.
    Fiorentino, V.
    Lauretti, L.
    Balducci, M.
    Pallini, R.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S53 - S53
  • [9] Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab
    Rahman, Rifaquat
    Hempfling, Kelly
    Norden, Andrew D.
    Reardon, David A.
    Nayak, Lakshmi
    Rinne, Mikael L.
    Beroukhim, Rameen
    Doherty, Lisa
    Ruland, Sandra
    Rai, Arun
    Rifenburg, Jennifer
    LaFrankie, Debra
    Alexander, Brian M.
    Huang, Raymond Y.
    Wen, Patrick Y.
    Lee, Eudocia Q.
    NEURO-ONCOLOGY, 2014, 16 (11) : 1523 - 1529
  • [10] Impact of adverse effects of bevacizumab on survival outcomes of patients swift recurrent glioblastoma.
    Hamza, Mohamed Ali
    Matsuoka, Carlos Kamiya
    De Groot, John Frederick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345